SAN DIEGO, Dec. 5, 2017 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
intratumoral cancer immunotherapies, today announced the promotion
of Christopher G. Twitty, Ph.D. to
Chief Scientific Officer. Dr. Twitty joined OncoSec in 2016 as
Executive Director of Clinical Science. He will join the executive
leadership team and report to Daniel J.
O'Connor, OncoSec's Chief Executive Officer. Dr.
Twitty brings over 20 years of experience in tumor immunology and
cancer immunotherapy, including the discovery and development of
OncoSec's leading clinical immune monitoring and biomarker
program.
"Dr. Twitty's demonstrated leadership and expertise have already
made him an integral part of our management team," said
Daniel J. O'Connor, Chief Executive
Officer of OncoSec. "His deep experience in translational
immunology and immune monitoring will continue to drive our
ImmunoPulse® IL-12 melanoma program forward and guide the
prioritization of our novel technology and product portfolio, which
we believe will address significant unmet medical needs in
oncology."
Dr. Twitty earned his PhD from Oregon Health & Science
University where his work was focused on novel tumor vaccine
strategies and was awarded an American Cancer Society fellowship
training grant for his post-doctoral studies in Dr. Bernard Fox's Molecular Tumor Immunology
Laboratory. After developing a preclinical and clinical
immunological program focused on glioblastoma at Tocagen, Dr.
Twitty joined Oncosec. Previously, Dr. Twitty held scientific
positions of increasing responsibility at Bayer Pharmaceuticals and
Cell Genesys, Inc.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based
intratumoral immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse
is designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as plasmid encoded IL-12
(tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical
trials, ImmunoPulse® IL-12 has demonstrated a favorable
safety profile, evidence of anti-tumor activity in the treatment of
various solid tumors, and the potential to reach beyond the site of
local treatment to initiate a systemic immune response. OncoSec's
lead program, ImmunoPulse IL-12, is currently in clinical
development for metastatic melanoma and triple-negative breast
cancer. The program's current focus is on the significant unmet
medical need in patients with melanoma who are refractory or have
relapsed on anti-PD-1 therapies. In addition to tavo, the Company
is also identifying and developing new immune-targeting agents for
use with the ImmunoPulse platform. For more information, please
visit www.oncosec.com.
CONTACT:
Investor Relations:
OncoSec Medical Incorporated
Phone: 855-662-6732
investors@oncosec.com
Media Relations:
OncoSec Medical Incorporated
Phone: 855-662-6732
media@oncosec.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosec-announces-promotion-of-christopher-g-twitty-phd-to-chief-scientific-officer-300566499.html
SOURCE OncoSec Medical Incorporated